NASDAQ:TCMD - Nasdaq - US87357P1003 - Common Stock - Currency: USD
9.64
-0.26 (-2.63%)
The current stock price of TCMD is 9.64 USD. In the past month the price decreased by -25.79%. In the past year, price decreased by -30.65%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.02 | 232.31B | ||
ISRG | INTUITIVE SURGICAL INC | 70.18 | 192.17B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.81 | 155.01B | ||
SYK | STRYKER CORP | 30.65 | 146.59B | ||
MDT | MEDTRONIC PLC | 15.57 | 106.66B | ||
BDX | BECTON DICKINSON AND CO | 11.86 | 47.99B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.86 | 44.12B | ||
IDXX | IDEXX LABORATORIES INC | 42.69 | 39.43B | ||
RMD | RESMED INC | 26.95 | 35.88B | ||
DXCM | DEXCOM INC | 50.52 | 32.68B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 14.96 | 31.51B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.41 | 22.46B |
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,037 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The firm markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The firm's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.
TACTILE SYSTEMS TECHNOLOGY I
3701 Wayzata Blvd, Suite 300
Minneapolis MINNESOTA 55416 US
CEO: Daniel L. Reuvers
Employees: 1037
Phone: 18664353948
The current stock price of TCMD is 9.64 USD. The price decreased by -2.63% in the last trading session.
The exchange symbol of TACTILE SYSTEMS TECHNOLOGY I is TCMD and it is listed on the Nasdaq exchange.
TCMD stock is listed on the Nasdaq exchange.
11 analysts have analysed TCMD and the average price target is 16.32 USD. This implies a price increase of 69.29% is expected in the next year compared to the current price of 9.64. Check the TACTILE SYSTEMS TECHNOLOGY I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TACTILE SYSTEMS TECHNOLOGY I (TCMD) has a market capitalization of 228.18M USD. This makes TCMD a Micro Cap stock.
TACTILE SYSTEMS TECHNOLOGY I (TCMD) currently has 1037 employees.
TACTILE SYSTEMS TECHNOLOGY I (TCMD) has a resistance level at 13.28. Check the full technical report for a detailed analysis of TCMD support and resistance levels.
The Revenue of TACTILE SYSTEMS TECHNOLOGY I (TCMD) is expected to grow by 8.57% in the next year. Check the estimates tab for more information on the TCMD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TCMD does not pay a dividend.
TACTILE SYSTEMS TECHNOLOGY I (TCMD) will report earnings on 2025-08-04, before the market open.
The PE ratio for TACTILE SYSTEMS TECHNOLOGY I (TCMD) is 14.61. This is based on the reported non-GAAP earnings per share of 0.66 and the current share price of 9.64 USD. Check the full fundamental report for a full analysis of the valuation metrics for TCMD.
The outstanding short interest for TACTILE SYSTEMS TECHNOLOGY I (TCMD) is 9.53% of its float. Check the ownership tab for more information on the TCMD short interest.
ChartMill assigns a fundamental rating of 6 / 10 to TCMD. TCMD has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months TCMD reported a non-GAAP Earnings per Share(EPS) of 0.66. The EPS decreased by -45.45% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 5.79% | ||
ROA | 5.69% | ||
ROE | 7.83% | ||
Debt/Equity | 0.11 |
ChartMill assigns a Buy % Consensus number of 78% to TCMD. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -7.34% and a revenue growth 8.57% for TCMD